Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of tinengotinib in advanced or metastatic cholangiocarcinoma after chemotherapy and FGFR inhibitor failure
CTR20232860Phase 2Completed
- Sponsor
- TransThera Biosciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tinengotinib in cholangiocarcinoma (CCA), sponsored by TransThera Biosciences. Primary endpoint: Confirmed objective response rate by BICR. Started Sep 2023; status: completed.
02
Drugs
tinengotinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on CTR20232860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232860.